BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
By Stephen Nakrosis
BeiGene on Thursday said the Food and Drug Administration approved Tevimbra to treat certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma, or ESSC.
The company said this was the first U.S. indication for Tevimbra, or tislelizumab-jsgr. The treatment will be available in the U.S. in the second half of this year, BeiGene said.
The FDA is reviewing biologics license applications for tislelizumab "as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC and patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma," BeiGene said.
Tislelizumab has been approved for certain patients with advanced or metastatic ESCC after prior chemotherapy. It received a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency earlier this year to treat non-small cell lung cancer across three indications, the oncology company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 14, 2024 17:22 ET (21:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth